Could DNA testing help the most seriously affected Covid-19 patients?

Last Updated on

April 28, 2020 – Coronavirus disease 2019 (Covid-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in December 2019 in Wuhan, the capital of China’s Hubei province, and has since spread globally, resulting in the ongoing 2019–20 coronavirus pandemicCommon symptoms of Covid-19 include fever, cough, fatigue, shortness of breath and loss of smell. While the majority of cases result in mild symptoms, some progress to viral pneumonia, multi-organ failure, or cytokine storm. These more concerning symptoms include difficulty breathing, persistent chest pain, confusion, difficulty waking, and bluish skin. The time from exposure to onset of symptoms is typically around five days but may range from two to fourteen days.

DNA testing could help in COVID-19 patient care

Testing, testing.

Strikingly, it seems that male individuals are much more affected by Covid-19 than female individuals and that the course of the disease is often much much serious, if not fatal in males. This observation is independent from the seeming bias towards the elderly for very serious disease. In this context, the question has arisen whether, besides different physiological. live style (e.g., fuming), and environmental risk factors that may predispose male to Covid-19, underlying genetic factors might play a role. This was the key hypothesis put forth in preliminary research published this month in bioRxiv that highlights the potential benefits of testing Covid-19 patients for genetic variants of the ACE2 gene, that codes for the ACE2 protein (i.e., the angiotensin converting  enzyme 2). ACE2 is already known to be the key point of entry for SARS-CoV-2 into human cells.

What makes the ACE2 gene very interesting in the observation of the startling differences in the Covid-19 death rates between men and women such as noted In the United Kingdom and the United States where men with Covid-19 are dying at twice the rate as women is the that the gene for ACE2 lies on the X chromosome, meaning men and boys only have a single version of the gene, while women and girls have two copies of this gene since they carry two copies of the X-chromosome in contrast to men and boys who carry only one copy of the X-chromosome. Thus, males who carry a rare ACE2 coding variants will express those variants (i.e., ACE2 allelic variants) in all ACE2-expressing cells, whereas females will typically express those variants in a mosaic distribution determined by early X-inactivation events. Recently, rare structural variants of the ACE2 gene have been described in the literature whose expressed proteins show some variations in their binding properties towards the SARS-CoV-2 spike protein. It is possible that in some individuals, if not all, the positive prognosis of the Covid‐19 may be due to the existence of ACE2 variants such as these described variants rs73635825 (S19P) and rs143936283 (E329G). Therefore, the findings of this investigation provide clues to screen frequencies of the candidate alleles in different populations to predict the prognosis of Covid‐19.

Of course, much more research needs still to be done in order to establish the genetics behind Covid-19. Typically, human geneticists would prefer to study the whole genomes of huge number of people infected with SARS-CoV-2 without choosing a preferred (i.e., a candidate  gene such as the ACE2 gene in the present case) gene at the beginning of their studies. That’s the best genetic way to identify factors that might influence why and how sick a patient might get. But during the present Covid-19 pandemic, there may not be enough time or resources to do this. In this situation, relaying on a candidate gene such as the ACE2 gene appears justified and might yield valuable information soon enough to help clinicians and patients alike in prospective disease risk evaluation and in taking treatment decisions. Around the world physicians are already making difficult decisions about who to treat and how; a genetic test around a candidate gene such as ACE2 could arm clinicians with the knowledge they need to intervene earlier in certain cases and thereby save more lives.

The quickest way to find these variants would be to examine the ACE2 gene in unusual cases of Covid-19, taking the so called “extreme phenotypes” approach. For example, children are less likely to come down with severe disease after being exposed to Covid-19, so any child with unusually severe Covid-19 (requiring ICU care, for example), could, in principle, have this gene sequenced where resources allow. Adding up the data from many, many children and adults would then reveal how these rare ACE2 variants truly affect disease severity.

Follow here this short illustrative sequence on SARS-CoV-2:

Print Friendly, PDF & Email

Tags: , , , , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion


No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Newly discovered mutation could point to heart disease therapeutic target August 7, 2020
    New work led by Carnegie's Meredith Wilson and Steve Farber identifies a potential therapeutic target for clogged arteries and other health risks that stem from an excess of harmful fats in the bloodstream. Their findings are published by PLOS Genetics.
  • Genetic cause of congenital malformation discovered August 7, 2020
    Spontaneous mutations of a single gene are likely to cause serious developmental disorders of the excretory organs and genitalia. This is shown in an international study led by the University of Bonn and published in the journal Frontiers in Cell and Developmental Biology. The researchers also owe their findings to an unusual model organism: the […]
  • Novel approach reduces SCA1 symptoms in animal model August 7, 2020
    Research has shown that a mutation in the ATAXIN-1 gene leads to accumulation of Ataxin-1 (ATXN1) protein in brain cells and is the root cause of a rare genetic neurodegenerative disease known as spinocerebellar ataxia type 1 (SCA1). How healthy cells maintain a precise level of ATXN1 has remained a mystery, but now a study […]
  • Alport Syndrome: Research highlights link between genotype and treatment effectiveness August 7, 2020
    A large-scale analysis of the clinical characteristics of Alport syndrome in Japanese patients has revealed that the effectiveness of existing treatment with ACE inhibitors and/or angiotensin receptor blockers (RAS inhibitors) varies depending on the type of mutation in the syndrome's causal gene (COL4A5). RAS inhibitors are widely administered to patients with chronic kidney diseases as […]
  • Tasmanian devil research offers new insights for tackling cancer in humans August 6, 2020
    A rare, transmissible tumor has brought the iconic Tasmanian devil to the brink of extinction, but new research by scientists at Washington State University and the Fred Hutchinson Cancer Research Center in Seattle indicates hope for the animals' survival and possibly new treatment for human cancers.
  • checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab August 8, 2020
    The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.
  • Phase 3 eXalt3 study shows significantly longer progression-free survival August 8, 2020
    Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib.
  • Addition of sintilimab to pemetrexed and platinum improved progression-free survival August 8, 2020
    The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented today at the International Association for the […]
  • Heart attack case rates, treatment approaches, outcomes during COVID-19 pandemic August 7, 2020
    The increases and decreases in patient volume and associated changes in treatment experienced by individuals presenting with acute heart attack (myocardial infarction) before and immediately after the onset of the COVID-19 pandemic are examined in this observational study.
  • COVID recovery choices shape future climate August 7, 2020
    A new international study, led by the University of Leeds, warns that even with some lockdown measures staying in place to the end of 2021, without more structural interventions global temperatures will only be roughly 0.01°C lower than expected by 2030. However, the study estimates that including climate policy measures as part of an economic […]